IGF1 and Ewing sarcoma: It is an appealing strategy using BET inhibitors to block the IGF1 autocrine mechanism in Ewing sarcoma patients with high IGF1R expression, which is expected to spare normal tissues from toxicity of anti-IGF1R therapy.